DUBLIN--(BUSINESS WIRE)--The "Hypereosinophilic Syndrome - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
The pipeline guide provides a snapshot of the global therapeutic landscape of Hypereosinophilic Syndrome (Hematological Disorders).
The pipeline guide reviews pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Hypereosinophilic Syndrome (Hematological Disorders) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Hypereosinophilic Syndrome (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Hypereosinophilic Syndrome (Hematological Disorders).
Companies Mentioned
- Bristol-Myers Squibb Co
- GlaxoSmithKline Plc
- Knopp Biosciences LLC
- Kyowa Hakko Kirin Co Ltd
- Stemline Therapeutics Inc
Key Topics Covered
- Introduction
- Report Coverage
- Hypereosinophilic Syndrome - Overview
- Hypereosinophilic Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Hypereosinophilic Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hypereosinophilic Syndrome - Companies Involved in Therapeutics Development
- Bristol-Myers Squibb Co
- GlaxoSmithKline Plc
- Knopp Biosciences LLC
- Kyowa Hakko Kirin Co Ltd
- Stemline Therapeutics Inc
- Hypereosinophilic Syndrome - Drug Profiles
- benralizumab - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- dasatinib - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- dexpramipexole dihydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- mepolizumab - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- SL-401 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Hypereosinophilic Syndrome - Dormant Projects
- Hypereosinophilic Syndrome - Product Development Milestones
- Featured News & Press Releases
For more information about this report visit https://www.researchandmarkets.com/research/xksj4w/pipeline_review?w=4